ESPERITE (ESP) postpones its EGM of 30th June 2020 due to remaining international sanitary risk and apologises for the short notice.
29 June 2020
Esperite N.V. (Euronext: ESP, “Esperite”) announces that the company is obliged to postpone the Extraordinary General Meeting of Shareholders (“EGM”) scheduled on 30 June 2020 at 14:00 hours CE in Amsterdam.
Esperite apologises for this short notice and will update its shareholders in the next coming days.
ESPERITE is a diversified investment company group specialized in Immunotherapy, Regenerative Medicine and Precision Medicine. Established in 2000, Esperite is a holding company, listed at Euronext Amsterdam and Paris. ESPERITE invests in companies able to transform the power of state-of-the-art technologies and scientific advancements into high quality products that bring the future of medicine to customers today at an affordable price.
ESPERITE provides early access to key information and knowledge, improving the way Science address human diseases and genetic disorders. ESPERITE attains the highest quality and ethical standards in the pursuit of its vision to bring the benefits of personalized medicine to society.
To learn more about the ESPERITE Group, or to book an interview with the CEO Frederic Amar: firstname.lastname@example.org or visit the websites at www.esperite.com